Identification of anaplastic lymphoma kinase fusions in renal cancer: Large-scale immunohistochemical screening by the intercalated antibody-enhanced polymer method

Cancer

Volumn 118, Issue 18, 2012, Pages 4427-4436

  Sugawara, Emiko ^a,b   Togashi, Yuki ^a   Kuroda, Naoto ^c   Sakata, Seiji ^a   Hatano, Satoko ^a   Asaka, Reimi ^a   Yuasa, Takeshi ^d   Yonese, Junji ^d   Kitagawa, Masanobu ^b   Mano, Hiroyuki ^e,f   Ishikawa, Yuichi ^a   Takeuchi, Kengo ^a  

^a CANCER INSTITUTE   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c KOCHI RED CROSS HOSPITAL   (Japan)

^d CANCER INSTITUTE HOSPITAL   (Japan)

^e JICHI MEDICAL UNIVERSITY   (Japan)

^f UNIVERSITY OF TOKYO   (Japan)

Author keywords

anaplastic lymphoma kinase; immunohistochemistry; intercalated antibody enhanced polymer; molecular targeted therapy; renal cell carcinoma

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; ANAPLASTIC LYMPHOMA KINASE; CAM5.2 PROTEIN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; COMPLEMENTARY DNA; CYTOKERATIN; CYTOKERATIN 34BETA E12; CYTOKERATIN 7; CYTOKERATIN AE1; CYTOKERATIN AE3; EPITHELIAL MEMBRANE ANTIGEN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR PAX2; TRANSCRIPTION FACTOR PAX8; TRANSCRIPTION TERMINATION FACTOR 1; UNCLASSIFIED DRUG; VIMENTIN;

ADULT; ANAPLASTIC LYMPHOMA KINASE GENE; ARTICLE; CLEAR CELL CARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; ECHINODERM MICROTUBULE ASSOCIATED PROTEIN LIKE 4 ANAPLASTIC LYMPHOMA KINASE GENE; ECHOGRAPHY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE FUSION; HEMATURIA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERCALATED ANTIBODY ENHANCED POLYMER METHOD; KIDNEY CANCER; KIDNEY CARCINOMA; KIDNEY COLLECTING TUBULE; KIDNEY COLLECTING TUBULE CARCINOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE; PAPILLARY CARCINOMA; PRIORITY JOURNAL; PYELONEPHRITIS; SARCOMATOID CARCINOMA; TROPOMYOSIN 3 ANAPLASTIC LYMPHOMA KINASE GENE;

ADOLESCENT; ADULT; CARCINOMA, RENAL CELL; CHILD; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; ONCOGENE PROTEINS, FUSION; POLYMERS; RECEPTOR PROTEIN-TYROSINE KINASES; VINCULIN;

EID: 84856978417     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27391     Document Type: Article

References (46)

1. International Agency for Research on Cancer. The GLOBOCAN Project: GLOBOCAN 2008. http://globocan.iarc.fr/. Accessed December 16, 2011.
2. Campbell SC, Novick AC, Bukowski RM,. Renal tumors. In:, Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA, eds. Campbell-Walsh Urology. 9th ed. Philadelphia, PA: Saunders; 2007: 1567-1637.
3. Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science. 1994; 263: 1281-1284.
4. Shiota M, Fujimoto J, Semba T, Satoh H, Yamamoto T, Mori S,. Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3. Oncogene. 1994; 9: 1567-1574.
5. Lawrence B, Perez-Atayde A, Hibbard MK, et al. TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors. Am J Pathol. 2000; 157: 377-384.
6. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007; 448: 561-566.
7. Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007; 131: 1190-1203.
8. Soda M, Takada S, Takeuchi K, et al. A mouse model for EML4-ALK-positive lung cancer. Proc Natl Acad Sci U S A. 2008; 105: 19893-19897.
9. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010; 363: 1693-1703.
10. Chihara D, Suzuki R,. More on crizotinib. N Engl J Med. 2011; 364: 776-777.
11. Butrynski JE, D'Adamo DR, Hornick JL, et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med. 2010; 363: 1727-1733.
12. Gambacorti-Passerini C, Messa C, Pogliani EM,. Crizotinib in anaplastic large-cell lymphoma. N Engl J Med. 2011; 364: 775-776.
13. Takeuchi K, Choi YL, Togashi Y, et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res. 2009; 15: 3143-3149.
14. Martelli MP, Sozzi G, Hernandez L, et al. EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. Am J Pathol. 2009; 174: 661-670.
15. Jokoji R, Yamasaki T, Minami S, et al. Combination of morphological feature analysis and immunohistochemistry is useful for screening of EML4-ALK-positive lung adenocarcinoma. J Clin Pathol. 2010; 63: 1066-1070.
16. Kijima T, Takeuchi K, Tetsumoto S, et al. Favorable response to crizotinib in three patients with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion-type oncogene-positive non-small cell lung cancer. Cancer Sci. 2011; 102: 1602-1604.
17. Kimura H, Nakajima T, Takeuchi K, et al. ALK fusion gene positive lung cancer and 3 cases treated with an inhibitor for ALK kinase activity. Lung Cancer. 2012; 75: 66-72.
18. Yoshida A, Tsuta K, Nakamura H, et al. Comprehensive histologic analysis of ALK-rearranged lung carcinomas. Am J Surg Pathol. 2011; 35: 1226-1234.
19. Yi ES, Boland JM, Maleszewski JJ, et al. Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH. J Thorac Oncol. 2011; 6: 459-465.
20. Kudo K, Takeuchi K, Tanaka H, et al. Immunohistochemical screening of ALK lung cancer with biopsy specimens of advanced lung cancer. J Clin Oncol. 2010; 28 (suppl): (abstract 10532).
21. Sakairi Y, Nakajima T, Yasufuku K, et al. EML4-ALK fusion gene assessment using metastatic lymph node samples obtained by endobronchial ultrasound-guided transbronchial needle aspiration. Clin Cancer Res. 2010; 16: 4938-4945.
22. Nakajima T, Kimura H, Takeuchi K, et al. Treatment of lung cancer with an ALK Inhibitor after EML4-ALK fusion gene detection using endobronchial ultrasound-guided transbronchial needle aspiration. J Thorac Oncol. 2010; 5: 2041-2043.
23. Takeuchi K, Soda M, Togashi Y, et al. Identification of a novel fusion, SQSTM1-ALK, in ALK-positive large B-cell lymphoma. Haematologica. 2011; 96: 464-467.
24. Takeuchi K, Soda M, Togashi Y, et al. Pulmonary inflammatory myofibroblastic tumor expressing a novel fusion, PPFIBP1-ALK: reappraisal of anti-ALK immunohistochemistry as a tool for novel ALK-fusion identification. Clin Cancer Res. 2011; 17: 3341-3348.
25. Shiota M, Fujimoto J, Takenaga M, et al. Diagnosis of t(2;5)(p23;q35)-associated Ki-1 lymphoma with immunohistochemistry. Blood. 1994; 84: 3648-3652.
26. Pulford K, Lamant L, Morris SW, et al. Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. Blood. 1997; 89: 1394-1404.
27. Shiota M, Nakamura S, Ichinohasama R, et al. Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: a distinct clinicopathologic entity. Blood. 1995; 86: 1954-1960.
28. Delsol G, Lamant L, Mariamé B, et al. A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2; 5 translocation. Blood. 1997; 89: 1483-1490.
29. Lamant L, Pulford K, Bischof D, et al. Expression of the ALK tyrosine kinase gene in neuroblastoma. Am J Pathol. 2000; 156: 1711-1721.
30. Takeuchi K, Choi YL, Soda M, et al. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res. 2008; 14: 6618-6624.
31. Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol. 2008; 3: 13-17.
32. Lopez-Beltran A, Carrasco JC, Cheng L, Scarpelli M, Kirkali Z, Montironi R,. 2009 update on the classification of renal epithelial tumors in adults. Int J Urol. 2009; 16: 432-443.
33. Delahunt B, Eble JN,. Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. Mod Pathol. 1997; 10: 537-544.
34. Yang XJ, Tan MH, Kim HL, et al. A molecular classification of papillary renal cell carcinoma. Cancer Res. 2005; 65: 5628-5637.
35. Mariño-Enríquez A, Ou WB, Weldon CB, Fletcher JA, Pérez-Atayde AR,. ALK rearrangement in sickle cell trait-associated renal medullary carcinoma. Genes Chromosomes Cancer. 2011; 50: 146-153.
36. Debelenko LV, Raimondi SC, Daw N, et al. Renal cell carcinoma with novel VCL-ALK fusion: new representative of ALK-associated tumor spectrum. Mod Pathol. 2011; 24: 430-442.
37. Argani P, Ladanyi M,. Renal carcinomas associated with Xp11.2 translocations/TFE3 gene fusions. In:, Eble J, Sauter G, Epstein J, Sesterhenn I, eds. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon, France: IARC Press; 2004: 37-38.
38. Ross H, Argani P,. Xp11 translocation renal cell carcinoma. Pathology. 2010; 42: 369-373.
39. Schmidt L, Junker K, Nakaigawa N, et al. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene. 1999; 18: 2343-2350.
40. Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol. 2009; 22: 508-515.
41. Lamant L, Dastugue N, Pulford K, Delsol G, Mariamé B,. A new fusion gene TPM3-ALK in anaplastic large cell lymphoma created by a (1;2)(q25;p23) translocation. Blood. 1999; 93: 3088-3095.
42. Lin E, Li L, Guan Y, et al. Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers. Mol Cancer Res. 2009; 7: 1466-1476.
43. Fukuyoshi Y, Inoue H, Kita Y, Utsunomiya T, Ishida T, Mori M,. EML4-ALK fusion transcript is not found in gastrointestinal and breast cancers. Br J Cancer. 2008; 98: 1536-1539.
44. Giuriato S, Faumont N, Bousquet E, et al. Development of a conditional bioluminescent transplant model for TPM3-ALK-induced tumorigenesis as a tool to validate ALK-dependent cancer targeted therapy. Cancer Biol Ther. 2007; 6: 1318-1323.
45. Sozzi G, Martelli MP, Conte D, et al. The EML4-ALK transcript but not the fusion protein can be expressed in reactive and neoplastic lymphoid tissues. Haematologica. 2009; 94: 1307-1311.
46. Rodig SJ, Mino-Kenudson M, Dacic S, et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res. 2009; 15: 5216-5223.